[C:1]([O:5][C@@H:6]([C:12]1[C:35]([CH3:36])=[CH:34][C:15]2[N:16]=[C:17]([C:19]3[S:20][CH:21]=[C:22]([C:24]4[CH:25]=[C:26]5[C:30](=[CH:31][CH:32]=4)[N:29]([CH3:33])[N:28]=[CH:27]5)[N:23]=3)[S:18][C:14]=2[C:13]=1[C:37]1[CH:42]=[CH:41][C:40]([Cl:43])=[CH:39][CH:38]=1)[C:7]([O:9]CC)=[O:8])([CH3:4])([CH3:3])[CH3:2].[OH-].[Na+]>C1COCC1.O>[C:1]([O:5][C@@H:6]([C:12]1[C:35]([CH3:36])=[CH:34][C:15]2[N:16]=[C:17]([C:19]3[S:20][CH:21]=[C:22]([C:24]4[CH:25]=[C:26]5[C:30](=[CH:31][CH:32]=4)[N:29]([CH3:33])[N:28]=[CH:27]5)[N:23]=3)[S:18][C:14]=2[C:13]=1[C:37]1[CH:38]=[CH:39][C:40]([Cl:43])=[CH:41][CH:42]=1)[C:7]([OH:9])=[O:8])([CH3:4])([CH3:2])[CH3:3]In a 25 mL round bottom flask, (S)-ethyl 2-tert-butoxy-2-(7-(4-chlorophenyl)-5-methyl-2-(4-(1-methyl-1H-indazol-5-yl)thiazol-2-yl)benzo[d]thiazol-6-yl)acetate (74 mg, 0.117 mmol) was dissolved in THF (3 mL) EtOH (2 mL) and water (1 mL). Then aqueous NaOH (2N) (1.17 mL) was added. The reaction mixture was stirred at 40° C. in oil bath for 17 h. The resulting reaction mixture was concentrated and purified on Gilson reverse phase preparative HPLC with 0-95% acetonitrile (with 0.1% TFA) in water (with 0.1% TFA) to afford product as a TFA salt. LCMS-ESI+: calc'd for: C31H27ClN4O3S2: 603.1, 605.1, 604.1 (M+H+); found: 603.2, 605.2, 604.0 (M+H+).1H NMR (400 MHz, CD3OD) δ 8.36 (d, J=1.2 Hz, 1H), 8.06-7.98 (m, 3H), 7.82 (s, 1H), 7.70 (dd, J=7.9, 2.4 Hz, 1H), 7.66-7.52 (m, 4H), 5.28 (s, 1H), 4.05 (s, 3H), 2.61 (s, 3H), 0.98 (s, 9H).
Wird geladen…